Prosecution Insights
Last updated: April 19, 2026

Kymera Therapeutics Inc.

11 pending office actions

Portfolio Summary

11
Total Pending OAs
2
Final Rejections
9
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18759253 CDK2 DEGRADERS AND USES THEREOF VAJDA, KRISTIN ANN 1622 Non-Final OA Jun 28, 2024
18559492 DEUTERATED IRAK DEGRADERS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 1622 Non-Final OA Nov 07, 2023
18486889 SALT FORMS OF IRAK4 DEGRADERS ISMAIL, REHANA 1625 Non-Final OA Oct 13, 2023
18453163 CDK2 INHIBITORS AND USES THEREOF SEITZ, ANTHONY JOSEPH 1629 Non-Final OA Aug 21, 2023
18547038 SMARCA DEGRADERS AND USES THEREOF BRAUN, MADELINE E 1624 Non-Final OA Aug 18, 2023
18265595 SMARCA DEGRADERS AND USES THEREOF SZNAIDMAN, MARCOS L 1628 Non-Final OA Jun 06, 2023
18030865 STAT DEGRADERS AND USES THEREOF MCANANY, JOHN D 1625 Non-Final OA Apr 07, 2023
18002116 IRAK DEGRADERS AND USES THEREOF RAO, SAVITHA M 1691 Non-Final OA Dec 16, 2022
17786807 IRAK DEGRADERS AND USES THEREOF SCHMIDT, IZABELA MARIA 1621 Final Rejection Jun 17, 2022
17597166 IRAK DEGRADERS AND USES THEREOF BURKETT, DANIEL JOHN 1624 Final Rejection Dec 28, 2021
17596495 SMARCA INHIBITORS AND USES THEREOF DAHLIN, HEATHER RAQUEL 1629 Non-Final OA Dec 10, 2021

Managing Kymera Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month